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Whole body and hematopoietic 
ADAM8 deficiency does not 
influence advanced atherosclerotic 
lesion development, despite its 
association with human plaque 
progression
Kosta Theodorou  1, Emiel P. C. van der Vorst1,2, Marion J. Gijbels1,3,4, Ine M. J. Wolfs1, Mike 
Jeurissen3, Thomas L. Theelen1, Judith C. Sluimer1, Erwin Wijnands1, Jack P. Cleutjens1, 
 Yu Li10, Yvonne Jansen2, Christian Weber2,5,6, Andreas Ludwig7, Jacob F. Bentzon8,9, Jörg W. 
Bartsch  10, Erik A. L. Biessen1,11 & Marjo M. P. C. Donners1
Although A Disintegrin And Metalloproteinase 8 (ADAM8) is not crucial for tissue development 
and homeostasis, it has been implicated in various inflammatory diseases by regulating processes 
like immune cell recruitment and activation. ADAM8 expression has been associated with human 
atherosclerosis development and myocardial infarction, however a causal role of ADAM8 in 
atherosclerosis has not been investigated thus far. In this study, we examined the expression of 
ADAM8 in early and progressed human atherosclerotic lesions, in which ADAM8 was significantly 
upregulated in vulnerable lesions. In addition, ADAM8 expression was most prominent in the shoulder 
region of human atherosclerotic lesions, characterized by the abundance of foam cells. In mice, Adam8 
was highly expressed in circulating neutrophils and in macrophages. Moreover, ADAM8 deficient 
mouse macrophages displayed reduced secretion of inflammatory mediators. Remarkably, however, 
neither hematopoietic nor whole-body ADAM8 deficiency in mice affected atherosclerotic lesion 
size. Additionally, except for an increase in granulocyte content in plaques of ADAM8 deficient mice, 
lesion morphology was unaffected. Taken together, whole body and hematopoietic ADAM8 does not 
contribute to advanced atherosclerotic plaque development, at least in female mice, although its 
expression might still be valuable as a diagnostic/prognostic biomarker to distinguish between stable 
and unstable lesions.
Atherosclerosis is a lipid-driven chronic inflammatory disease, initiated by endothelial dysfunction, resulting 
in the subendothelial accumulation and modification of circulating lipoprotein particles, together with the 
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recruitment of leukocytes within the vessel wall. These modified lipoproteins are internalized by macrophages, 
forming foam cells which eventually become apoptotic. Progressed atherosclerotic lesions are characterized by 
the formation of a fibrous cap and a lipid rich necrotic core1. These lesions may, upon rupture, lead to local throm-
bosis, the major cause of clinical events such as myocardial infarction and stroke2.
A Disintegrin And Metalloproteinases (ADAMs) are a family of transmembrane proteases which play a role in 
modulating inflammatory responses3. Their role in cardiovascular diseases (CVD)/ atherosclerosis is emerging as 
evidenced by several recent publications showing that ADAM10 modulates atherosclerotic plaque composition4, 
while ADAM15 contributes to lesion development5 and ADAM17 provides with atherosclerosis resistance6, 7. 
Among several members of this family, ADAM8 exhibits sheddase activity, enabling cleavage of atherosclerosis 
related cell surface proteins, including the inflammatory molecules L-selectin, P-selectin glycoprotein ligand-1 
(PSGL-1), tumor necrosis factor (TNF), TNF receptor 1 and vascular cell adhesion molecule 18, 9. ADAM8 is 
highly expressed in most cells of hematopoietic origin, and in the brain, bone, lung and thymus10–15. Despite being 
widely expressed, mice deficient in ADAM8 have a normal development with no overt phenotype15. With respect 
to pathologies, ADAM8 levels increase in cancer and inflammatory diseases of the lung, central nervous system, 
bone and joints, and its expression positively correlates with disease severity11, 16–18.
ADAM8 expression was also upregulated in human atherosclerotic plaques compared to non-atherosclerotic 
control vessels19. Moreover, this study showed specific ADAM8 polymorphisms (rs2995300C and rs2275725A) 
to be associated with atherosclerosis development and myocardial infarction in two independent human cohorts. 
However, it is unclear whether ADAM8 is also causally involved in atherosclerosis development. In this study, 
we investigated whether ADAM8 plays a role in the development and progression of atherosclerotic lesions. 
Although we show that ADAM8 expression is associated with lesion progression in human disease, genetic abla-
tion of ADAM8 both in the hematopoietic compartment as well as at whole-body level did not affect advanced 
atherosclerosis development in female mice.
Results
ADAM8 expression increases with atherosclerotic plaque progression in humans and is mainly 
associated with foam cell-rich regions. Reanalysis of a previous microarray study20 (GSE7074) from 
our laboratory comparing human atherosclerotic plaque macrophages and resident macrophages derived 
from liver, lung and spleen revealed ADAM8 as one of the highest upregulated genes in plaque macrophages 
(Fig. 1a), which prompted us to investigate ADAM8 gene expression in different stages of human atherosclerotic 
Figure 1. ADAM8 expression in human atherosclerotic lesions. (a) Microarray expression profiling of 
carotid atherosclerotic plaque macrophages and lung, liver and spleen macrophages (n = 4 patients per tissue, 
nonparametric Mann-Whitney U test). (b) Relative expression of ADAM8 mRNA in early, advanced stable and 
unstable human plaques. Values have been corrected for GAPDH expression (n = 5–6) and ADAM8 expression 
levels in early plaques were normalized to 1 (one way analysis of variance followed by Dunn’s multiple 
comparison test). (c,d) Immunohistochemical stainings for ADAM8 in human atherosclerotic lesions. (c) 
Representative images of a shoulder region (scale bar, 400 μm), a region rich in foamy macrophages (scale bar, 
50 μm) and a negative control (d, scale bar, 200 μm) are shown.
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plaque development. Tissue lysates from early, stable and unstable human lesions showed significantly increased 
ADAM8 mRNA expression in unstable lesions (Fig. 1b).
Immunohistochemical staining of ADAM8 in human carotid atherosclerotic plaques confirmed the expres-
sion of ADAM8 in lesions at the protein level. ADAM8 expression was not only found in leukocytes (as previously 
reported13), but also in luminal and microvascular endothelial cells and, potentially, vascular smooth muscle 
cells (suppl. Figure 1a and b). ADAM8 localized intensely to the shoulder regions of the plaque (Fig. 1c), an area 
mainly composed of inflammatory cells21.
Adam8 is mainly expressed in neutrophils and macrophages and modulates secretion of 
inflammatory mediators. Leukocytes play a pivotal role in both human and murine atherosclerosis devel-
opment22. In homeostatic conditions, expression of ADAM8 is mainly restricted to cells of the immune sys-
tem8. We therefore sought to examine its expression in various leukocyte subsets isolated from wildtype C57Bl/6 
mice. Interestingly, Adam8 mRNA is mainly expressed in circulating neutrophils and, to a lower extent, in bone 
marrow-derived macrophages (BMDMs; Fig. 2a). In contrast, expression of Adam8 mRNA in monocytes and B- 
and T-lymphocytes was barely detectable. ADAM8 expression was reported to increase under pathological condi-
tions11, 16–18. Since macrophages are the main inflammatory cell type in mouse atherosclerotic plaques where they 
will be exposed to (modified) lipoproteins23, we investigated Adam8 expression in BMDMs exposed to different 
types of lipoproteins. Interestingly, while Adam8 mRNA levels were not affected by very low-density lipopro-
teins (VLDLs) or low-density lipoproteins (LDL), oxidized LDL increased ADAM8 mRNA (Fig. 2b) and protein 
(Fig. 2c) expression in BMDMs. This is in line with the pronounced ADAM8 expression in foamy macrophages of 
human atherosclerotic plaques (Fig. 1c). Since ADAMs play a crucial role in modulating inflammatory responses, 
we examined the role of ADAM8 in LPS-induced cytokine production by BMDMs. Interestingly, ADAM8 defi-
ciency resulted in significantly reduced TNFα, interleukin (IL)-10 and IL-12 as well as nitric oxide (NO) secre-
tion, both when BMDMs were pre-exposed to oxLDL followed by LPS or LPS alone (Fig. 2d).
Hematopoietic ADAM8 deficiency does not affect size or composition of advanced athero-
sclerotic lesions. Considering its expression in hematopoietic cells and its role in modulating macrophage 
inflammatory responses, we investigated the effect of hematopoietic deficiency of ADAM8 on lesion development 
Figure 2. Adam8 expression in leukocyte subsets and ADAM8 deficient BMDMs show reduced inflammatory 
response. (a) Relative Adam8 mRNA expression in sorted murine C57Bl/6 blood B-lymphocytes, 
T-lymphocytes, monocytes, neutrophils, resident peritoneal macrophages and BMDMs (n = 4 mice). Fold 
changes of Adam8/Gapdh expression is shown. (b) Adam8 expression in wildtype C57Bl/6 BMDMs exposed 
for 24 h to 0.25 μg/ml VLDL, LDL or oxLDL (n = 2 per group). (c) Western blot analysis of BMDMs stimulated 
with PBS or 0.25 μg/ml oxLDL (n = 3 per group). (d) Cytokine or nitric oxide (NO) secretion by Adam8+/+ and 
Adam8−/− BMDMs that were pre-treated with PBS or 0.25 μg/ml oxLDL for 24 hours, followed by a 6 hours 
(TNFα and IL-10) or 24 hours (IL-12 and NO) incubation with PBS or 10 ng/ml LPS (n = 3 mice per group, 
nonparametric Mann-Whitney U test).
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by reconstituting lethally irradiated female low-density lipoprotein deficient (Ldlr−/−) mice with bone marrow 
from either ADAM8 deficient (Adam8−/− → Ldlr−/−) mice or wildtype (Adam8+/+ → Ldlr−/−) littermate controls. 
The efficiency of the bone marrow transplantation (BMT) was 96% ± 0.1. After reconstitution, mice were fed a 
western type diet (WTD) for 10 weeks after which lesions development was assessed. No differences between 
genotypes were found in body weight (suppl. Figure 2a) or plasma cholesterol before and after WTD (Fig. 3a). 
Although at baseline triglyceride levels in Adam8−/− → Ldlr−/− mice were slightly decreased compared to 
Adam8+/+ → Ldlr−/− mice, no differences were observed upon WTD (Fig. 3b). Furthermore, after recovery from 
the BMT, circulating leukocyte counts were analyzed by flow cytometry. Both at baseline (before WTD) and after 
10 weeks of WTD the total number of CD45+ leukocytes in blood was significantly reduced in hematopoietic 
ADAM8 deficient mice compared to wildtype controls (suppl. Figure 2b and c). ADAM8 deficiency associated 
leukopenia affected almost all major leukocyte (sub)populations.
After 10 weeks of WTD feeding, atherosclerotic lesion area was not affected by hematopoietic ADAM8 defi-
ciency, both in the aortic root (Fig. 3c) and brachiocephalic artery (suppl. Figure 2d). Furthermore, there was 
no change in necrotic core content between both groups in the aortic root (Fig. 3d). Routine pathological exam-
ination for atherosclerotic plaque progression (Fig. 3e) as well as (immuno)histochemical stainings for mac-
rophage (Fig. 3e), neutrophil (Fig. 3f) and collagen content (Fig. 3g) showed no significant differences between 
Adam8−/− → Ldlr−/− and Adam8+/+ → Ldlr−/− mice. Moreover, mRNA levels of Arg1 and Nos2, were unchanged 
between both genotypes (suppl. Figure 2e), suggesting no difference in macrophage polarization. Moreover, we 
did not observe a compensatory upregulation of the related metalloprotease Adam17. Altogether, these data show 
that, despite reduced amounts of circulating leukocytes, hematopoietic ADAM8 deficiency does not influence 
advanced atherosclerotic lesion development or composition.
Advanced atherosclerotic lesions are not affected by whole-body ADAM8 deficiency. Most 
ADAM family members are expressed as transmembrane proteases. ADAM8, however, also exists in a soluble 
form comprising the, functional, metalloproteinase domain only24, 25. Although significantly lower compared to 
wildtype controls, hematopoietic ADAM8 deficient mice still have considerable plasma levels of soluble ADAM8 
(suppl. Figure 2f) most likely originating from non-hematopoietic cells which may have compensated for the 
hematopoietic deficiency.
To exclude this possibility, we rendered female whole-body Adam8−/− and wildtype littermate controls prone 
to atherosclerosis by using a recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) overex-
pressing adeno-associated viral vector in combination with WTD feeding26. Indeed, PCSK9 overexpression raised 
both plasma cholesterol and triglyceride levels upon WTD feeding to a similar extent as in Ldlr−/− mice, but both 
were not found different between Adam8−/− and wildtype mice (Fig. 4a and b), despite a lower body weight in 
Adam8−/− mice after 10 weeks of WTD (suppl. Figure 3a). Additionally, blood leukocyte counts were measured 
using flow cytometry before animals were subjected to WTD feeding and at sacrifice (suppl. Figure 3b and c). In 
contrast to hematopoietic ADAM8 deficient mice, no leukopenia was observed and whole-body ADAM8 defi-
ciency even resulted in slightly increased T cell and NK cell counts under hyperlipidemic conditions.
Surprisingly, even whole-body ADAM8 deficiency did not affect atherosclerotic lesion size in the brachio-
cephalic artery (suppl. Figure 3d) and aortic root (Fig. 4c). Similar to hematopoietic ADAM8 deficient mice, 
necrotic core content (Fig. 4d), plaque stage (Fig. 4e), as well as (immuno)histochemical staining of macrophage 
(Fig. 4f) and collagen content (Fig. 4h) showed no difference in whole body Adam8 knockout mice compared 
to wildtype controls. Moreover, Arg1, Nos2 and Adam17 mRNA expression was similar between both genotypes 
(suppl. Figure 3e). However, the amount of granulocytes was significantly increased in ADAM8 deficient mice 
compared to wildtype mice (Fig. 4g). Collectively, these data show that both hematopoietic as well as whole-body 
ADAM8 deficiency does not affect advanced atherogenesis in mice.
Discussion
This is the first study that investigated the role of ADAM8 in atherosclerosis development. Although, we clearly 
showed that ADAM8 expression is increased in unstable human atherosclerotic lesion, we did not observe any 
effects of hematopoietic nor whole-body ADAM8 on advanced atherosclerosis development in mice.
Originally identified in a human macrophage cell line27, ADAM8 is mainly expressed in most cells of hemato-
poietic origin, both under physiological as well as inflammatory conditions13, 28. Here, we show that in mice, 
under physiological conditions, Adam8 indeed is highly expressed in circulating neutrophils and to a lower 
extent in bone marrow derived macrophages. In contrast, Adam8 is hardly expressed by monocytes and lympho-
cytes, in agreement with open access mouse leukocyte expression databases (immgen.org). Similarly, in humans 
ADAM8 was also seen to be expressed by neutrophils25 and monocytes13, 29, while T lymphocytes lack ADAM8 
expression13. Interestingly, however, human B lymphocytes do express ADAM8, albeit to a lower extent com-
pared to human monocytes13. These findings suggest species differences in hematopoietic ADAM8 expression, 
at least in T and B lymphocytes. Next to neutrophils, macrophages express higher levels of Adam8 than mono-
cytes and lymphocytes under physiological conditions. Interestingly, peritoneal macrophages, which are a subset 
of resident macrophages, express similar low Adam8 levels as monocytes. The difference in Adam8 expression 
between freshly differentiated macrophages from bone marrow cells and resident macrophages might be due to 
the difference in their local microenvironment which initiate different transcriptional programs30 or their mode 
of differentiation31.
The atherosclerotic plaque harbors multiple environmental cues which dynamically regulate the expression 
profiles of macrophages32. Previously, it has been shown that ADAM8 gene and protein expression increase upon 
atherosclerotic lesion development in humans, and that its expression co-localized with plaque smooth mus-
cle cells and macrophages33. In this study, we show that ADAM8 is especially abundant in the plaque shoulder 
regions, which are rich in leukocytes, especially (foamy) macrophages. Furthermore, oxLDL, which is abundantly 
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Figure 3. Hematopoietic ADAM8 deficiency in Ldlr−/− mice does not affect size or morphology of advanced 
atherosclerotic lesions. (a,b) Plasma cholesterol (a) and triglyceride (b) levels after 0, 5 and 10 weeks 
of western type diet (WTD) feeding in female Ldlr−/− chimeras with (Adam8−/− → Ldlr−/−) or without 
(Adam8+/+ → Ldlr−/−) hematopoietic ADAM8 deficiency (n = 20 mice per genotype, parametric Student’s t-
test). (c, d) Quantification of the aortic root lesion area (c, non-parametric Mann-Whitney U test) and necrotic 
core area (d, parametric Student’s t-test) of Adam8+/+ → Ldlr−/− and Adam8−/− → Ldlr−/− mice (n = 18 mice per 
genotype) after 10 weeks of WTD. (e) Plaque progression stage (n = 51 aortic root atherosclerotic lesions per 
genotype) was scored (Fisher’s exact test). (f–h) Representative examples of (immuno)histochemical stainings 
and quantifications for MOMA-2+ macrophages (f, n = 18/16 mice, parametric Student’s t-test, scale bar, 200 
μm), NIMP+ neutrophils (g, n = 18/16 mice, non-parametric Mann-Whitney U test, scale bar, 50 μm) and Sirius 
Red stained collagen (h, n = 18/16 mice, parametric Student’s t-test, scale bar, 200 μm) in the aortic root after 10 
weeks of WTD feeding.
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Figure 4. Whole-body ADAM8 deficiency has no effect on advanced plaque size or morphology. (a,b) Plasma 
cholesterol (a) and triglyceride (b) levels of female whole-body wildtype (Adam8+/+) and Adam8−/− mice 
rendered hyperlipidemic by AAV8-PCSK9 gene transfer and subsequent western type diet (WTD) feeding, at 
start of WTD diet (0) and after 5 and 10 weeks (n = 16/14 mice, parametric Student’s t-test). (c,d) Quantification 
of the aortic root lesion area (c, n = 14/13 mice, nonparametric Mann-Whitney U test) and necrotic core area 
(d, n = 14/13 mice, nonparametric Mann-Whitney U test) of whole body Adam8+/+ and Adam8−/− mice after 
10 weeks of WTD feeding. (e) Plaque stage classification (n = 42/39 atherosclerotic lesions in the aortic root) 
was scored (Fisher’s exact test). (f–h) Representative examples of (immuno)histochemical stainings for MAC-3+ 
macrophages (f, n = 14/13 mice, parametric Student’s t-test scale bar, 200 μm), Ly6G+ granulocytes (g, n = 14/13 
mice, nonparametric Mann-Whitney U test scale bar, 50 μm) and Sirius Red stained collagen (h, n = 14/13 
mice, nonparametric Mann-Whitney U test scale bar, 200 μm) with quantification.
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present in atherosclerotic lesions and can modify macrophage phenotype and function23, was seen to upregulate 
ADAM8 expression, unlike LDL and VLDL. Interestingly, ADAM8 deficient mouse macrophages have an atten-
uated secretion of inflammatory mediators, including TNF, a proposed substrate of ADAM834. Despite ADAM17 
being the main TNF sheddase both in vitro and in vivo35, 36, ADAM8 deficiency has a significant contribution to 
TNF release in vitro. We found both pro-and anti-inflammatory cytokines to be reduced, i.e. no clear M1 or M2 
profile, in line with unchanged Nos2 and Arg-1 expression in plaques in vivo.
Remarkably, despite the absence of any effects of hematopoietic ADAM8 deficiency on atherosclerosis devel-
opment, these bone marrow transplanted mice displayed a slight decrease in triglyceride levels at baseline and 
mild leukopenia both under normo- and hyperlipidemic conditions. Although only evident during recovery after 
bone marrow transplantation, the potential role of hematopoietic ADAM8 deficiency in triglyceride metabolism 
remains to be determined. Regarding the observed leukopenia, ADAM8 has previously been shown to regulate 
the surface expression of the adhesion molecules L-selectin and PSGL-1 through shedding25, 28. Interestingly, 
ligation of PSGL-1 on hematopoietic progenitor cells to P-selectin results in suppression of hematopoiesis37. 
Additionally, L-selectin may function as a retention cue for granulocytes to remain in the bone marrow38, 39. 
Although ADAM8 might indirectly affect both processes, via these two substrates, the fact that whole-body 
ADAM8 deficient mice failed to display leukopenia does not plead for this notion. Another possibility for this 
discrepancy might lie in a role for ADAM8 in the homing of progenitor cells towards the bone marrow niche after 
BMT.
Furthermore, ADAM8-mediated shedding of the adhesion molecules L-selectin and PSGL-1 may also control 
neutrophil recruitment25, 28. ADAM8 deficiency results in increased surface expression of both molecules, which 
will lead to increased tethering of neutrophils to endothelial cells40. In line, atherosclerotic lesions of whole-body 
ADAM8 deficient mice contained increased amounts of granulocytes compared to their respective controls. In 
contrast, hematopoietic ADAM8 deficiency did not result in an accumulation of neutrophils in atherosclerotic 
lesions, albeit this might be due to the presence of sufficient levels of plasma sADAM8, which also has the capacity 
to cleave transmembrane proteins, like L-selectin. Indeed, transgenic mice that overexpressed the soluble form of 
ADAM8 display a reduction in surface expression of L-selectin and concomitantly a decrease in leukocyte accu-
mulation in the peritoneal cavity after receiving an inflammatory stimulus41. Similarly, overexpression of ADAM8 
might also attenuate leukocyte recruitment towards atherosclerotic lesions, and thus reduce atherosclerotic bur-
den. On the other hand, however, overexpression of ADAM8 may also increase the inflammatory response of 
macrophages and other cell types that have the capacity to secrete TNFα34. Therefore, ADAM8 affects processes 
that inhibit or exacerbate atherosclerosis development, which could explain why we did not observe any change in 
plaque size or morphology in female ADAM8 deficient mice. Note, although no reports on sex specific effects of 
ADAM8 have been reported, we cannot exclude the possibility that ADAM8 differentially affects atherosclerosis 
development in males.
In addition to the potential dual effects of ADAM8 in atherosclerosis, other ADAMs with a similar sub-
strate profile as ADAM8, such as ADAM1742, might at least partly compensate for the loss of ADAM8. ADAM17 
expression was unchanged between ADAM8 wildtype and knockout mice in both atherosclerosis models, sug-
gesting there is no overcompensation for the loss of ADAM8 deficiency although this does not rule out any 
functional compensation.
Furthermore, neutrophils are involved in the process of atherosclerosis, primarily during the initiation of 
lesion development43. Therefore, it cannot be excluded that ADAM8 might have an effect at earlier developmental 
stages, since all atherosclerotic lesions in this study were classified as moderate to advanced.
We and others33, 44 have shown that ADAM8 expression is increased in advanced human atherosclerotic 
lesions. Next to its expression in macrophages, especially in foam cells located at the shoulder region of the ather-
osclerotic lesion, ADAM8 was also expressed in plaque stromal cells, including endothelial cells and, potentially, 
smooth muscle cells, though the role of ADAM8 in these vascular cell types is less defined. Risk allele carriers 
have increased serum levels of soluble ADAM8 and an increased risk of myocardial infarction19, which shows that 
ADAM8 may still have clinical potential.
In conclusion, while ADAM8 affects inflammatory responses in vitro, our data argue against a critical role for 
both hematopoietic and whole-body ADAM8 in atherosclerosis development in female mice, at least in advanced 
stages of the disease. However, ADAM8 may still be useful as a diagnostic/prognostic biomarker to distinguish 
between stable and unstable atherosclerotic lesions in humans, though further research is needed.
Materials and Methods
Microarray and quantitative PCR analysis of human tissues. Human carotid artery plaque tissue45 
and nonatherosclerotic (lung, liver, spleen) tissues20 were obtained by endarterectomy or autopsies, respectively, 
as previously described. Collection, storage and use of tissue in the Maastricht Pathology Tissue Collection 
(MPTC) and patient data confidentiality were performed after informed consent and in agreement with the 
‘Code for Proper Secondary Use of Human Tissue in the Netherlands’ and in accordance with the guidelines of, 
and approved by the medical and ethical committee of Maastricht University Medical Centre, Maastricht, The 
Netherlands. Sample processing, macrophage isolation and microarray hybridization and analysis of the differ-
ences between carotid plaque, lung, liver and spleen macrophages was performed as previously described (Gene 
Expression Omnibus database accession number GSE7074)20. Carotid lesion segments for quantitative PCR anal-
ysis were snap-frozen and subsequently RNA was isolated using the guanidine isothiocyanate/CsCl method as 
previously described45. RNA was further purified and concentrated using RNeasy mini columns (Qiagen). Total 
RNA was normalized and reverse transcribed using iScript (Biorad). Quantitative PCR (qPCR) was performed 
using 10 ng cDNA, 300 nM of each primer, and SensiMix (Quantace-Bioline). All gene expression levels were 
corrected for cyclophilin A and ß-actin as housekeeping genes.
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Immunohistochemistry of human tissues. Human carotid endarterectomy segments were fixed in par-
aformaldehyde and paraffin embedded. Sections were incubated with a primary antibody against human ADAM8 
(AF1031, R&D systems), followed by detection with a biotin-labelled rabbit anti-goat antibody (E0466, Dako) 
and Vector Red ABC kit (Vector Labs, CA, USA). Atherosclerotic lesions were classified as introduced by Virmani 
et al.46. Pathological intimal thickening or xanthomata were defined as ‘early’, thick fibrous cap atheroma ‘stable’ 
and lesions with a thrombus or intraplaque hemorrhage ‘unstable’ lesions.
Animals. Mouse experiments were approved by the Animal Ethics Committee of Maastricht University, the 
Netherlands (permit number 2012-065), and were performed in compliance with the Dutch government guide-
lines. Female Ldlr−/− mice were obtained from an in-house breeding colony, originally derived from Charles 
River (Wilmington, MA, USA). Female Adam8 knockout (Adam8−/−) and wildtype (Adam8+/+) littermate con-
trol mice on a C57Bl/6 background were previously described and generously provided by Dr. J. Bartsch15.
Peritoneal macrophage isolation. Resident peritoneal macrophages were obtained by flushing the peri-
toneal cavity with ice-cold phosphate buffered saline (PBS) followed by culturing in RPMI 1640 Glutamax con-
taining 10% (vol/vol) heat inactivated fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100ug/ml), 
and L-glutamine 2 mM (all GIBCO Invitrogen, Breda, the Netherlands). After overnight attachment, cells were 
washed three times with RPMI 1640 Glutamax to remove non-adherent cells. Adherent cells were dissolved in 
TRIzol reagent (Life Technologies) and stored at −20 °C until further use.
Bone marrow-derived macrophage isolation and culture. Bone marrow cells were isolated from 
femurs and tibiae of either Adam8−/− or wildtype littermate controls. Cells were cultured in RPMI 1640 Glutamax 
(GIBCO Invitrogen, Breda, the Netherlands) with 10% (vol/vol) heat-inactivated FCS (Bodinco B.V. Alkmaar, the 
Netherlands), penicillin (100 U/ml) and streptomycin (100 μg/ml) supplemented with 15% L929-conditioned 
medium (LCM) for 8 days to generate bone-marrow derived macrophages (BMDMs). BMDMs were seeded at 
0.35 × 106 cells per well in 24 wells plates and incubated 6-24 hours with 10 ng/ml LPS (E. Coli 055:B5, Sigma). 
Alternatively, BMDMs were incubated for 24 hours with 25 μg/ml very-low density lipoprotein (VLDL), low den-
sity lipoprotein (LDL) or oxidized LDL (oxLDL). VLDL and LDL were isolated from human serum47 and LDL 
oxidatively modified by CuSO4 as previously described48. Supernatants were collected and stored at −20 °C until 
further use.
Fluorescence-activated cell sorting. Leukocyte subsets were isolated from blood collected from wildtype 
C57Bl/6 mice using a FACS Aria (BD Biosciences). Erythrocytes were removed by incubation with erylysis buffer 
(155 mM NH4Cl and 10 mM KHCO3). Leukocytes were defined as CD45+ (Biolegend), T-lymphocytes as CD45+ 
CD3+ (eBioscience) NK1.1− (BD), B-lymphocytes as CD45+ CD3− NK1.1− B220+ (BD), granulocytes as CD45+ 
CD3− NK1.1− B220− CD11b+ (BD) Ly6G+ (BD) and monocytes as CD45+ CD3− NK1.1− B220− CD11b+ Ly6G−.
Quantitative PCR in murine cells. RNA from FACS sorted cells and murine aortic arches was isolated 
using TRIzol (Life Technologies) or RNeasy mini kit (Qiagen), respectively, according to the manufacturer’s 
instructions. RNA (500 ng) was reverse transcribed using the iScript cDNA Synthesis Kit (Biorad). Quantitative 
PCR was performed using 10 ng cDNA, 300 nmol/L of each primer and Sensimix SYBR Green (Biorad) in a 
total volume of 12 μL. All gene expression levels were expressed relative to Gapdh as housekeeping genes. Primer 
sequences are available upon request.
ELISA. TNF, IL-10 (after 6 h LPS) and IL-12p40 (after 24 h LPS) levels in BMDM-derived conditioned 
medium were measured with ELISA kits (Invitrogen) according to the manufacturer’s instructions. Plasma sol-
uble ADAM8 was measured using a commercial ELISA kit (Hoelzel Diagnostica, Cologne, Germany) according 
the manufacturer’s instructions. Analysis was performed using a micro-plate reader (Biorad).
NO assay. NO2− concentrations were determined in LPS-induced BMDM-derived conditioned medium 
using Griess reagent (2.5% H3PO4, 1% sulphanilamide, 0.1% naphthalene diamine dihydochloride) and measured 
at 540 nm (benchmark microplate reader, Biorad).
Western Blot analysis. After a 24 hours incubation with PBS or 25 μg/ml oxLDL, BMDMs were treated 
lysis buffer (150 mM NaCl, 50 mM Tris, 10 mM EDTA, 1% NP-40, 8.7% glycerol, 0.1% SDS) supplemented with 
1x Complete Inhibitor (Roche). After centrifugation at 16.000 x g for 5 min, supernatants were collected and 
protein concentration was determined using bicinchoninic acid (BCA) assay (Thermofisher). Supernatants were 
investigated by reducing SDS-PAGE as previously described4. Proteins were transferred onto nitrocellulose mem-
brane (GE Healthcare Life Sciences). Membranes were blocked with 5% (w/v) non-fat dry milk in Tris buffered 
saline with 0.1% Tween (TBS-T) for 1 hour, cut into two horizontal strips based on the predicted molecular 
weights of the target proteins, and then probed with primary antibody against murine ADAM849 (Abcam) or 
β-actin (Abcam) overnight, followed by appropriate horseradish peroxidase conjugated secondary antibodies. 
Chemiluminescence was detected using ImageQuant LAS 4000 mini (GE Healthcare Life Sciences). Images of 
full-length blots are shown in suppl. Figure 4.
Bone marrow transplantation and atherosclerotic lesion analyses. Female wildtype and Adam8−/− 
mice (aged 10 to 12 weeks) were used as donor mice (n = 4 per group). Female Ldlr−/− recipient mice (10 weeks 
old, n = 18 per group), backcrossed onto a C57Bl/6 background for >10 generations, were obtained from in-house 
breeding. Bone marrow transplantations (BMT) were performed as described elsewhere45. Briefly, Ldlr−/− mice 
were lethally irradiated with 6 Gy a day before and on the day of transplantation. Mice were transplanted with 
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5 × 106 bone marrow cells isolated from wildtype or Adam8−/− mice. After a recovery period of 5 weeks after 
transplantation, mice were given a western type diet (WTD) containing 0.25% cholesterol (Special Diets Services, 
Witham, Essex, UK). Before WTD feeding, mice were fasted for 4 hours, after which blood samples were drawn 
from the tail vein for analyses of plasma lipids, chimerism, soluble ADAM8 and leukocytes. Additional blood 
analyses were performed at 5 and 10 weeks of WTD, after 4 hours fasting. After 10 weeks of WTD feeding, mice 
were anesthetized, euthanized and perfused with PBS containing nitroprusside (0.1 mg/ml, Sigma).
Mouse hearts were dissected and snap-frozen in optimum cutting temperature medium. Serial cryosections 
(7 μm) of the aortic root and brachiocephalic artery were fixed in acetone and stained with toluidine blue for 
morphometric analysis of plaque and necrotic core area (defined as acellular regions). Total plaque area per 
mouse was defined as the average plaque area of four consecutive toluidine blue-stained sections at 42 μm inter-
vals. Plaque stages were determined as previously described50, with slight modifications. Plaques were classified 
as early (foam cell rich, but lacking a necrotic core), moderately advanced (containing a fibrotic cap and often a 
necrotic core, but no medial macrophage infiltration) and advanced lesions, typified by medial macrophage infil-
trates, elastic lamina degradation and more pronounced necrosis and fibrosis. MOMA-2 (an antibody recogniz-
ing monocytes/macrophages; gift from G. Kraal), NIMP-1 (neutrophil specific antibody directed against Ly6G; 
gift from P. Heeringa) and Sirius Red (Sigma) staining was used for the detection of monocytes/macrophages, 
neutrophils and collagen, respectively. Pictures were taken using a Leica DM3000 light microscope (Leica 
Microsystems, Wetzlar, Germany) and sections were analyzed in a blinded manner using Adobe Photoshop CS6 
software (Adobe, San Jose, US).
Atherosclerotic lesion analysis in whole-body ADAM8 deficient mice. Female wildtype and 
Adam8−/− mice (aged 10 to 12 weeks; n = 16 and 14, respectively) were rendered prone to atherosclerosis by a sin-
gle intravenous injection of adeno-associated virus serotype 8 containing D377Y-murine PCSK9 (AAV-PCSK9; 
1 × 1011 vector genomes per mouse; as described previously26), followed by WTD feeding (0.25% cholesterol; 
Special Diets Services, Witham, Essex, UK). Blood was collected from the tail vein for analyses of plasma lipids 
at baseline (before WTD) and after 5 and 10 weeks of WTD feeding after 4 hours fasting. After 10 weeks of 
WTD feeding, mice were anesthetized, euthanized and perfused with PBS containing nitroprusside (0.1 mg/ml, 
Sigma). Mouse hearts were excised and fixed overnight in 1% paraformaldehyde. Serial paraffin sections of the 
aortic root and brachiocephalic artery were cut (4 μm) and stained with hematoxylin and eosin (H&E, Sigma) 
for morphometric analysis of plaque and necrotic core area (defined as acellular regions), and plaque staging, as 
described in the BMT section. Total plaque area per mouse was defined as the average plaque area of five consecu-
tive H&E-stained sections at 20 μm intervals. Atherosclerotic lesions were further characterized for macrophage 
(MAC3, BD), granulocyte (Ly6G, Becton & Dickenson) and collagen (Sirius Red) content. Similar as to the BMT 
setup, pictures were taken using a Leica DM3000 light microscope and sections were analyzed in a blinded man-
ner using Adobe Photoshop CS6 software.
Flow cytometry analyses and blood lipid analyses. Absolute circulating leukocyte subset numbers 
were determined by flow cytometry calibrated using Trucount Beads (BD, New Jersey, US). Blood was collected 
at the start (t = 0) and after 10 weeks of WTD. Erythrocytes were removed by incubation with erylysis buffer 
(155 mM NH4Cl and 10 mM KHCO3). Leukocytes were defined as CD45+ (Biolegend), T-lymphocytes as CD45+ 
CD3+ (eBioscience) NK1.1− (BD), NK cells as CD45+ CD3− NK1.1+, B-lymphocytes as CD45+ CD3− NK1.1− 
B220+ (BD) granulocytes as CD45+ CD3− NK1.1− B220− CD11b+ (BD) Ly6G+ (BD) and monocytes as CD45+ 
CD3− NK1.1− B220− CD11b+ Ly6G−. Monocyte subsets were further distinguished based on the degree of Ly6C 
expression. Data were acquired using a FACS Canto II (BD Bioscience) and analyzed with FACSdiva software 
(BD Bioscience).
Blood was collected at the start (t = 0) and after 5 and 10 weeks of WTD. Plasma was separated by centrifuga-
tion (2100 x g, 10 minutes, 4 °C), and stored at -80 °C until further use. Plasma cholesterol and triglycerides were 
determined using standard enzymatic kits (Cholesterol FS’10; Triglycerides FS 5’ Ecoline; Diagnostic Systems 
GmbH, Holzheim, Germany) according to the manufacturer’s instructions.
Statistics. Data are presented as mean ± SEM. All statistical analyses were performed using the Prism soft-
ware (GraphPad Software version 5, San Diego, CA, USA). Differences between two groups or more were eval-
uated for statistical significance with the appropriate Student’s t test, Mann-Whitney U test, Fisher’s exact test or 
one-way analysis of variance followed by Dunn’s multiple comparisons test, respectively. P values of less than 0.05 
were considered significant.
References
 1. Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nature immunology 12, 204–212, doi:10.1038/ni.2001 
(2011).
 2. Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D. & Virmani, R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc 
Biol 30, 1282–1292, doi:10.1161/ATVBAHA.108.179739 (2010).
 3. Dreymueller, D., Pruessmeyer, J., Groth, E. & Ludwig, A. The role of ADAM-mediated shedding in vascular biology. European 
journal of cell biology 91, 472–485, doi:10.1016/j.ejcb.2011.09.003 (2012).
 4. van der Vorst, E. P. et al. Myeloid A disintegrin and metalloproteinase domain 10 deficiency modulates atherosclerotic plaque 
composition by shifting the balance from inflammation toward fibrosis. The American journal of pathology 185, 1145–1155, 
doi:10.1016/j.ajpath.2014.11.028 (2015).
 5. Sun, C., Wu, M. H., Lee, E. S. & Yuan, S. Y. A disintegrin and metalloproteinase 15 contributes to atherosclerosis by mediating 
endothelial barrier dysfunction via Src family kinase activity. Arterioscler Thromb Vasc Biol 32, 2444–2451, doi:10.1161/
ATVBAHA.112.252205 (2012).
 6. Holdt, L. M., Thiery, J., Breslow, J. L. & Teupser, D. Increased ADAM17 mRNA expression and activity is associated with 
atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 28, 1097–1103, doi:10.1161/
ATVBAHA.108.165654 (2008).
www.nature.com/scientificreports/
1 0SCIENTIfIC RepoRTS | 7: 11670  | DOI:10.1038/s41598-017-10549-x
 7. Nicolaou, A. et al. Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice. Arterioscler Thromb Vasc 
Biol. doi:10.1161/ATVBAHA.116.308682 (2016).
 8. Edwards, D. R., Handsley, M. M. & Pennington, C. J. The ADAM metalloproteinases. Mol Aspects Med 29, 258–289, doi:10.1016/j.
mam.2008.08.001 (2008).
 9. van der Vorst, E. P., Keijbeck, A. A., de Winther, M. P. & Donners, M. M. A disintegrin and metalloproteases: molecular scissors in 
angiogenesis, inflammation and atherosclerosis. Atherosclerosis 224, 302–308, doi:10.1016/j.atherosclerosis.2012.04.023 (2012).
 10. Ainola, M. et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone 
destruction. Ann Rheum Dis 68, 427–434, doi:10.1136/ard.2008.088260 (2009).
 11. Foley, S. C. et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol 119, 
863–871, doi:10.1016/j.jaci.2006.12.665 (2007).
 12. Gossens, K., Naus, S., Hollander, G. A. & Ziltener, H. J. Deficiency of the metalloproteinase-disintegrin ADAM8 is associated with 
thymic hyper-cellularity. PLoS One 5, e12766, doi:10.1371/journal.pone.0012766 (2010).
 13. Richens, J. et al. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on 
peripheral blood B cells, dendritic cells and monocyte subsets. Immunobiology 212, 29–38, doi:10.1016/j.imbio.2006.06.012 (2007).
 14. Johansson, M. W. et al. Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am J Respir Cell Mol Biol 31, 
413–422, doi:10.1165/rcmb.2004-0099OC (2004).
 15. Kelly, K. et al. Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice. Dev Dyn 232, 221–231, 
doi:10.1002/dvdy.20221 (2005).
 16. Valkovskaya, N. et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic 
cancer. J Cell Mol Med 11, 1162–1174, doi:10.1111/j.1582-4934.2007.00082.x (2007).
 17. Oreo, K. M. et al. Sputum ADAM8 expression is increased in severe asthma and COPD. Clin Exp Allergy 44, 342–352, doi:10.1111/
cea.12223 (2014).
 18. Schlomann, U., Rathke-Hartlieb, S., Yamamoto, S., Jockusch, H. & Bartsch, J. W. Tumor necrosis factor alpha induces a 
metalloprotease-disintegrin, ADAM8 (CD 156): implications for neuron-glia interactions during neurodegeneration. J Neurosci 20, 
7964–7971 (2000).
 19. Raitoharju, E. et al. Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial 
infarction in two independent cohorts. Atherosclerosis 218, 127–133, doi:10.1016/j.atherosclerosis.2011.05.005 (2011).
 20. Eijgelaar, W. J., Horrevoets, A. J., Bijnens, A. P., Daemen, M. J. & Verhaegh, W. F. Equivalence testing in microarray analysis: 
similarities in the transcriptome of human atherosclerotic and nonatherosclerotic macrophages. Physiol Genomics 41, 212–223, 
doi:10.1152/physiolgenomics.00193.2009 (2010).
 21. Pasterkamp, G. et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature 
in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol 19, 54–58 (1999).
 22. Weber, C., Zernecke, A. & Libby, P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse 
models. Nat Rev Immunol 8, 802–815, doi:10.1038/nri2415 (2008).
 23. Shiffman, D. et al. Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem 275, 37324–37332, 
doi:10.1074/jbc.M004732200 (2000).
 24. Naus, S. et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem 
387, 337–346, doi:10.1515/BC.2006.045 (2006).
 25. Gomez-Gaviro, M. et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological 
activation and its catalytic activity on L-selectin shedding. J Immunol 178, 8053–8063 (2007).
 26. Bjorklund, M. M. et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res 114, 
1684–1689, doi:10.1161/CIRCRESAHA.114.302937 (2014).
 27. Yoshida, S., Setoguchi, M., Higuchi, Y., Akizuki, S. & Yamamoto, S. Molecular cloning of cDNA encoding MS2 antigen, a novel cell 
surface antigen strongly expressed in murine monocytic lineage. Int Immunol 2, 585–591 (1990).
 28. Nishimura, D. et al. Roles of ADAM8 in elimination of injured muscle fibers prior to skeletal muscle regeneration. Mech Dev 135, 
58–67, doi:10.1016/j.mod.2014.12.001 (2015).
 29. Yoshiyama, K., Higuchi, Y., Kataoka, M., Matsuura, K. & Yamamoto, S. CD156 (human ADAM8): expression, primary amino acid 
sequence, and gene location. Genomics 41, 56–62, doi:10.1006/geno.1997.4607 (1997).
 30. Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312–1326, 
doi:10.1016/j.cell.2014.11.018 (2014).
 31. Lehtonen, A. et al. Gene expression profiling during differentiation of human monocytes to macrophages or dendritic cells. J Leukoc 
Biol 82, 710–720, doi:10.1189/jlb.0307194 (2007).
 32. Chistiakov, D. A., Bobryshev, Y. V. & Orekhov, A. N. Changes in transcriptome of macrophages in atherosclerosis. J Cell Mol Med 19, 
1163–1173, doi:10.1111/jcmm.12591 (2015).
 33. Levula, M. et al. ADAM8 and its single nucleotide polymorphism 2662 T/G are associated with advanced atherosclerosis and fatal 
myocardial infarction: Tampere vascular study. Ann Med 41, 497–507, doi:10.1080/07853890903025945 (2009).
 34. Bartsch, J. W. et al. Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-
disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection. J Neurosci 30, 12210–12218, doi:10.1523/
JNEUROSCI.1520-10.2010 (2010).
 35. Horiuchi, K. et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents 
lethality from endotoxin shock. J Immunol 179, 2686–2689 (2007).
 36. Bell, J. H., Herrera, A. H., Li, Y. & Walcheck, B. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by 
neutrophils and macrophages. J Leukoc Biol 82, 173–176, doi:10.1189/jlb.0307193 (2007).
 37. Levesque, J. P. et al. PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in suppression of 
hematopoiesis. Immunity 11, 369–378 (1999).
 38. Rogowski, O. et al. Down-regulation of the CD62L antigen as a possible mechanism for neutrophilia during inflammation. Br J 
Haematol 101, 666–669 (1998).
 39. Kassirer, M. et al. The appearance of L-selectin(low) polymorphonuclear leukocytes in the circulating pool of peripheral blood 
during myocardial infarction correlates with neutrophilia and with the size of the infarct. Clin Cardiol 22, 721–726 (1999).
 40. Dominguez-Luis, M. et al. The metalloprotease ADAM8 is associated with and regulates the function of the adhesion receptor 
PSGL-1 through ERM proteins. Eur J Immunol 41, 3436–3442 (2011).
 41. Higuchi, Y., Yasui, A., Matsuura, K. & Yamamoto, S. CD156 transgenic mice. Different responses between inflammatory types. 
Pathobiology 70, 47-54, doi:66003 (2002).
 42. Li, Y., Brazzell, J., Herrera, A. & Walcheck, B. ADAM17 deficiency by mature neutrophils has differential effects on L-selectin 
shedding. Blood 108, 2275–2279, doi:10.1182/blood-2006-02-005827 (2006).
 43. Drechsler, M., Megens, R. T., van Zandvoort, M., Weber, C. & Soehnlein, O. Hyperlipidemia-triggered neutrophilia promotes early 
atherosclerosis. Circulation 122, 1837–1845, doi:10.1161/CIRCULATIONAHA.110.961714 (2010).
 44. Pelisek, J. et al. Expression and cellular localization of metalloproteases ADAMs in high graded carotid artery lesions. Scand J Clin 
Lab Invest 72, 648–656, doi:10.3109/00365513.2012.734394 (2012).
 45. Legein, B. et al. Ablation of CD8alpha(+) dendritic cell mediated cross-presentation does not impact atherosclerosis in 
hyperlipidemic mice. Sci Rep 5, 15414, doi:10.1038/srep15414 (2015).
www.nature.com/scientificreports/
1 1SCIENTIfIC RepoRTS | 7: 11670  | DOI:10.1038/s41598-017-10549-x
 46. Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. & Schwartz, S. M. Lessons from sudden coronary death: a comprehensive 
morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20, 1262–1275 (2000).
 47. Redgrave, T. G., Roberts, D. C. & West, C. E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal 
Biochem 65, 42–49 (1975).
 48. Hendriks, W. L., van der Boom, H., van Vark, L. C. & Havekes, L. M. Lipoprotein lipase stimulates the binding and uptake of 
moderately oxidized low-density lipoprotein by J774 macrophages. Biochem J 314(Pt 2), 563–568 (1996).
 49. Dreymueller, D. et al. The metalloproteinase ADAM8 promotes leukocyte recruitment in vitro and in acute lung inflammation. Am 
J Physiol Lung Cell Mol Physiol, ajplung 00444, 02016, doi:10.1152/ajplung.00444.2016 (2017).
 50. Gijbels, M. J. et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. 
Atherosclerosis 143, 15–25 (1999).
Acknowledgements
M.M.P.C.D. and K.T. are supported by Dr. E. Dekker grant 20120T79, E.P.C.v.d.V. by CARIM PhD-award, 
Deutsche Forschungsgemeinschaft (SFB 1123-A1) and the Alexander von Humboldt Foundation.
Author Contributions
M.M.P.C.D. designed the study and analysed the data. K.T. conducted whole-body Adam8−/− atherosclerosis 
studies and analysed the data. E.P.C.v.d.V. conducted hematopoietic Adam8−/− atherosclerosis studies and 
analysed the data. K.T., Y.L. and E.P.C.v.d.V. performed in vitro experiments and processed ELISA and qPCR 
data. T.L.T. did the mouse handling. I.M.J.W. and M.J. processed the mouse tissues. M.J.G. performed the 
routine pathological examination. E.W. conducted flow cytometry experiments. J.S., J.P.C., Y.J., C.W., J.F.B., 
A.L, J.W.B. contributed critical reagents/materials/mice/analysis software. K.T. and E.P.C.v.d.V. drafted the 
initial manuscript. K.T., E.P.C.v.d.V., E.A.L.B., and M.M.P.C.D. discussed and revised the manuscript. K.T. and 
E.P.C.v.d.V. contributed equally to the study. All authors discussed the results and commented on the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10549-x
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
